ERRATUM

Erratum to: Tafamidis in transthyretin amyloidosis: a guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy

Kate McKeage¹ · Katherine A. Lyseng-Williamson¹ · Lesley J. Scott¹

Published online: 1 February 2017
© Springer International Publishing Switzerland 2017

Erratum to: Drugs Ther Perspect DOI 10.1007/s40267-016-0368-4

In the online version of the original article, Fig. 2 is incorrect.

The correct version is given below.

The online version of the original article (as corrected) can be found under doi:[10.1007/s40267-016-0368-4](https://doi.org/10.1007/s40267-016-0368-4).

✉ Katherine A. Lyseng-Williamson
dtp@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand

Patient care guidelines

Fig. 2 Patient care guidelines for the treatment of stage 1 transthyretin familial amyloid polyneuropathy (TTR-FAP), as suggested by Adams et al. [4]